AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie FDA Breakthrough Therapy Designations by Year
FDA Breakthrough Therapy Designations (designations)
AbbVie FDA Breakthrough Therapy Designations: 1 in FY2025, unchanged from a year earlier.
Latest, FY2025
1
Period ended Dec 31, 2025
Change on a year earlier
0.0%
1 in FY2024
History
3 years
Since FY2023
Sources
1
AbbVie 2025 ESG Action Report
Where the FY2025 figure comes from
“Percentage of Compounds in FDA Breakthrough Therapy Employees in R&D Positions12 Late-Stage Clinical Development Designations Granted by Year with Novel Mechanism of Action Business Sustainability 80% 1 1 1 ~15,000 56% 50% 2023 2024 2025 2023 2024 2025 2023 2024* 2025”
Source: AbbVie 2025 ESG Action Report ↗
Reported in AbbVie ESG Action Reports.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | FDA Breakthrough Therapy Designations (designations) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | 0.0% | AbbVie 2025 ESG Action Report ↗ |
| FY2024 | Dec 31, 2024 | 1 | 0.0% | AbbVie 2025 ESG Action Report ↗ |
| FY2023 | Dec 31, 2023 | 1 | – | AbbVie 2025 ESG Action Report ↗ |
Cite this data
StockData. (2026). AbbVie FDA Breakthrough Therapy Designations, annual FY2023–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-fda-breakthrough
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.